dopamine < dopaminergic < dopaminomimetic

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 40.
[0-20] [0 - 20][0 - 40][20-40]

Ident.	Authors (with country if any)	Title
000072 (2013)	Ji Hyun Ko [Canada] ; Francesca Antonelli [Canada] ; Oury Monchi [Canada] ; Nicola Ray [Canada] ; Pablo Rusjan [Canada] ; Sylvain Houle [Canada] ; Anthony E. Lang [Canada] ; Leigh Christopher [Canada] ; Antonio P. Strafella [Canada]	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease
000081 (2013)	Alex A. Macdonald [Canada] ; Oury Monchi [Canada] ; Ken N. Seergobin [Canada] ; Hooman Ganjavi [Canada] ; Ruzbeh Tamjeedi [Canada] ; Penny A. Macdonald [Canada]	Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function
000179 (2012)	Sandra Noble [Canada] ; Abid Ismail [Canada] ; Rafael Godoy [Canada] ; Yanwei Xi [Canada] ; Marc Ekker [Canada]	Zebrafish Parla‐ and Parlb‐deficiency affects dopaminergic neuron patterning and embryonic survival
000362 (2011)	Bruno Rezende Souza [Canada] ; Vincent Tropepe [Canada]	The role of dopaminergic signalling during larval zebrafish brain development: a tool for investigating the developmental basis of neuropsychiatric disorders
000396 (2011)	Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada]	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
000418 (2011)	L. Macgillivray [Canada] ; K. B. Reynolds [Canada] ; M. Sickand [Canada] ; P. I. Rosebush [Canada] ; M. F. Mazurek [Canada]	Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra
000449 (2011)	Alberto J. Espay [États-Unis] ; Joe P. Giuffrida [États-Unis] ; Robert Chen [Canada] ; Megan Payne [États-Unis] ; Filomena Mazzella [Canada] ; Emily Dunn [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Andrew P. Duker [États-Unis] ; Alok Sahay [États-Unis] ; Sang Jin Kim [Canada] ; Fredy J. Revilla [États-Unis] ; Dustin A. Heldman [États-Unis]	Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease
000491 (2010)	Yanwei Xi [Canada] ; Joel Ryan [Canada] ; Sandra Noble [Canada] ; Man Yu [Canada] ; Ayse E. Yilbas [Canada] ; Marc Ekker [Canada]	Impaired dopaminergic neuron development and locomotor function in zebrafish with loss of pink1 function
000493 (2010)	Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew J. Lees [Royaume-Uni]	Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
000639 (2010)	A. Jon Stoessl [Canada]	Continuous dopaminergic therapy in Parkinson disease: Time to stride back?
000673 (2009)	C. Warren Olanow [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; Anthony E. Lang [Canada] ; Jose A. Obeso [Espagne]	Dopaminergic transplantation for parkinson's disease: Current status and future prospects
000740 (2009)	O. K. Sujith [Canada] ; Carol Lane [Canada]	Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease
000777 (2009)	Na K. Kim [Corée du Sud] ; Byung H. Choi [Corée du Sud] ; Xian Huang [Corée du Sud] ; Brian J. Snyder [Canada] ; Shefqat Bukhari [Canada] ; Tae-Ho Kong [Corée du Sud] ; Hyeonseon Park [Corée du Sud] ; Hyung C. Park [Corée du Sud] ; So R. Park [Corée du Sud] ; Yoon Ha [Corée du Sud]	Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model
000963 (2008)	M. Quinn [Canada] ; K. Mukhida [Canada] ; D. Sadi [Canada] ; M. Hong [Canada] ; I. Mendez	Adjunctive use of the non‐ionic surfactant Poloxamer  188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease
000A39 (2007)	Wei Zhang [États-Unis, République populaire de Chine] ; Shannon Dallas [États-Unis] ; Dan Zhang [États-Unis] ; Jian-Ping Guo [Canada] ; Hao Pang [États-Unis] ; Belinda Wilson [États-Unis] ; David S. Miller [États-Unis] ; Biao Chen [République populaire de Chine] ; Wanqin Zhang [République populaire de Chine] ; Patrick L. Mcgeer [Canada] ; Jau-Shyong Hong [États-Unis] ; Jing Zhang [États-Unis]	Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein
000A69 (2007)	Quincy J. Almeida [Canada] ; James S. Frank [Canada] ; Eric A. Roy [Canada] ; Aftab E. Patla [Canada] ; Mandar S. Jog [Canada]	Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease
000C70 (2005)	D. Mcfarlane ; N. Dybdal [États-Unis] ; M. T. Donaldson [États-Unis] ; L. Miller [Canada] ; A. E. Cribb	Nitration and Increased α‐Synuclein Expression Associated With Dopaminergic Neurodegeneration In Equine Pituitary Pars Intermedia Dysfunction
000F86 (2001)	J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis]	Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study
001164 (2000)	K. Adam Baker [Canada] ; Damaso Sadi [Canada] ; Murray Hong [Canada] ; Ivar Mendez [Canada]	Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: Role of the intranigral graft
001206 (2000)	Chong S. Lee [Canada] ; Ali Samii [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Jess Wudel [Canada] ; Pramod K. Pal [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
001223 (2000)	Marie-Josée Bourque [Canada] ; Louis-Eric Trudeau [Canada]	GDNF enhances the synaptic efficacy of dopaminergic neurons in culture

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i -k "dopaminergic" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i  \
                -Sk "dopaminergic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Istex
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Title.i
   |clé=    dopaminergic
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022